<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2018</study_start_year><condition>Colon Neoplasms</condition><condition>Colon Cancer</condition><condition>Colonic Cancer</condition><condition>Cancer of the Colon</condition><condition>Neoplasms, Colonic</condition><condition>Neoplasms</condition><condition>Colonic Neoplasms</condition><disease>Colon Neoplasms</disease><disease>Colonic Cancer</disease><disease>Colon Cancer</disease><disease>Neoplasms, Colonic</disease><disease>Cancer Of The Colon</disease><disease>Neoplasms</disease><disease>Colonic Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2266868</full_dataset_link><location>United States</location><study_start_month>3</study_start_month><keyword>Palbociclib</keyword><keyword>Metastatic colon cancer</keyword><keyword>Cetuximab</keyword><repository>ECRIN MDR</repository><study_status>Active, not recruiting</study_status></additional><is_claimable>false</is_claimable><name>Palbociclib and Cetuximab in Metastatic Colorectal Cancer</name><description>This research study is designed to provide a better understanding of study drugs cetuximab (Erbitux) and palbociclib when used in combination to treat patients with metastatic colon cancer.</description><dates><creation>2018-03-15</creation></dates><accession>2266868</accession><cross_references><ClinicalTrials___gov>NCT03446157</ClinicalTrials___gov></cross_references></HashMap>